🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

138 results for “Bristol” Clear

  1. KarX-EC, KarXT, KarX-EC matching placebo, KarX-EC, KarXT, KarXT, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  2. KarXT

    Bristol-Myers Squibb

    Bipolar Disorder Type I With Mania

    phase 3 small molecule active

    1 trial

  3. KarXT

    Bristol-Myers Squibb

    Irritability Associated With Autism Spectrum Disorder

    phase 3 small molecule active

    1 trial

  4. KarXT, KarX-EC matching Placebo, KarX-EC, KarXT matching Placebo, KarXT, KarX-EC, KarX-EC, KarX-EC, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  5. KarXT, KarX-EC, KarX-EC, KarXT, KarXT, KarX-EC matching Placebo, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  6. KarXT, KarXT Matching Placebo, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Schizophrenia

    phase 3 small molecule active

    1 trial

  7. KarXT, KarXT, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Mania or Mania with Mixed Features in Bipolar-I Disorder

    phase 3 small molecule active

    1 trial

  8. KarXT, KarXT, KarXT, KarXT Matching Placebo

    Bristol-Myers Squibb Australia Pty Ltd

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  9. KarXT, KarXT, KarXT, KarXT, KarXT Matching Placebo

    Bristol-Myers Squibb Australia Pty Ltd

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  10. KarXT, KarXT, KarXT, KarXT, KarXT, Placebo

    Bristol-Myers Squibb Australia Pty Ltd

    Psychosis Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  11. KarXT, KarXT, KarXT, Karxt Matching Placebo

    Bristol-Myers Squibb Australia Pty Ltd

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  12. LPA1 antagonist, LPA1 antagonist, Placebo for BMS-986278

    Bristol-Myers Squibb Australia Pty Ltd

    Idiopathic pulmonary fibrosis

    phase 3 small molecule active

    1 trial

  13. LPA1 antagonist, Placebo for BMS-986278, LPA1 antagonist

    Bristol-Myers Squibb Australia Pty Ltd

    Progressive Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  14. Lonsurf 15 mg/6.14 mg film-coated tablets, Relatlimab + Nivolumab Fixed Dose Combination (FDC), Lonsurf 20 mg/8.19 mg film-coated tablets, Stivarga 40 mg film-coated tablets

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  15. MRTX1719, CARBOPLATIN, CISPLATIN, PEMETREXED, MRTX1719 Matching Placebo, PACLITAXEL ALBUMIN-BOUND, PEMBROLIZUMAB, PACLITAXEL

    Bristol-Myers Squibb Australia Pty Ltd

    metastatic non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  16. Muraglitazar

    Bristol-Myers Squibb

    Diabetes, Type 2

    phase 3 small molecule completed

    1 trial

  17. NKTR-214

    Bristol-Myers Squibb

    Melanoma

    phase 3 mab completed

    1 trial

  18. Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Participants with completely resected Stage III or Stage IV melanoma

    phase 3 small molecule active

    1 trial

  19. Nivolumab

    Bristol-Myers Squibb

    Head and Neck Cancer

    phase 3 mab completed

    1 trial

  20. Nivolumab

    Bristol-Myers Squibb

    Colorectal Cancer

    phase 3 mab completed

    1 trial

  21. Nivolumab

    Bristol-Myers Squibb

    Brain Neoplasms

    phase 3 small molecule completed

    1 trial

  22. Nivolumab

    Bristol-Myers Squibb

    Bladder Cancer

    phase 3 mab completed

    1 trial

  23. Nivolumab

    Bristol-Myers Squibb

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  24. Nivolumab Subcutaneous, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources